Pipeline

Astex Pharmaceuticals™ has established a broad pipeline of small molecule, molecularly targeted drugs using its drug discovery engine, Pyramid™. Pyramid™ is also used to support the Company’s drug discovery collaborations with leading pharmaceutical company partners.

Program / Mechanism / Indication

Phase 1

Phase 2

Phase 3

Marketed

Partner

DACOGEN® – Hypomethylator (MDS)
  • Eisai
  • Janssen
DACOGEN® – Hypomethylator (AML)
  • Eisai
  • Janssen
AT13387 – HSP90 inhibitor (GIST)
  •  
SGI110 – DNMT inhibitor (MDS + AML)
  •  
Amuvatinib/MP470 (SCLC)
  •  
AT7519 – CDK inhibitor (MM)
  • Novartis
*
AT9283 – JAK/Aurora inhibitor (MM)
  •  
AT13148 – AGC kinase inhibitor
  • Cancer Research Technology
  • The Institute of Cancer Research
* Optioned.

Partnered Products and Programs

Compound Name / Mechanism

Discovery

Preclinical

Phase 1

Phase 2

Partner

LEE011 – CDK4 inhibitor (Oncology)
  • Novartis
AZD5363 – PKB/Akt inhibitor (Oncology)
  • AstraZeneca
FGFr inhibitor (Oncology)
  • Janssen
AZDXXXX – BACE inhibitor (Alzheimer’s)
  • AstraZeneca
Multiple discovery milestones achieved
Multiple targets (Multiple therapeutic areas)
  • gsk
Discovery Obligations Completed
Partner targets (Oncology)
  • Janssen